Q4 FY26 Quarterly Activities Report and Appendix 4C

• Successfully completed USAISR Phase II in-vitro platelets testing with high-quality, 94.4% post-thaw platelet recovery
• Secured partnerships with U.S. blood collection networks Vitalant and Hoxworth
• Completed annual cryopreservation season for aquaculture, increasing throughput year-on-year by ~68%
• Raised $32m via institutional placement and share purchase plan
• Ended the quarter with $41.2m in cash and term deposits

Vitrafy Life Sciences Limited (ASX: VFY) reported its Q4 FY26 Quarterly Activities Report and Appendix 4C Cash Flow report, highlighting successful completion of USAISR Phase II in-vitro platelets testing with 94.4% post-thaw platelet recovery, new partnerships with U.S. blood collection networks Vitalant and Hoxworth, increased aquaculture throughput by ~68% year-on-year, and a $32m capital raise via institutional placement and share purchase plan. The company ended the quarter with $41.2m in cash and term deposits.

Vitrafy is focused on securing FDA medical device registration, establishing U.S. manufacturing, and building out resources to serve the U.S. market.